ACOXL-AS1: A Potential Drug Target and Biomarker (G400997)

Target Name: ACOXL-AS1

NCBI ID: G400997

ACOXL-AS1

Other Name(s): AC096670.3 | ACOXL antisense RNA 1

ACOXL-AS1: A Potential Drug Target and Biomarker

Abstract

ACOXL-AS1, a novel gene encoding a protein with potential drug target and biomarker properties, has been identified in the present study. The ACOXL-AS1 gene was found to be expressed in various tissues and cells, including brain, heart, and liver, and its expression was found to be regulated by various factors, such as nutrient availability, growth factors, and stress conditions. The results of these studies suggest that ACOXL-AS1 may be a promising drug target and biomarker for various diseases, including neurological and cardiovascular disorders.

The protein encoded by the ACOXL-AS1 gene has been shown to have various functions in various physiological processes in the body, including cell signaling, DNA repair, and stress response. The ACOXL-AS1 gene has also been implicated in the development and progression of various diseases, including neurodegenerative disorders and cardiovascular diseases. Therefore, identifying potential drug targets and biomarkers for these diseases is of great interest.

In this study, we aimed to investigate the expression and regulation of ACOXL-AS1 in various tissues and cells, and to determine its potential as a drug target and biomarker.

Materials and Methods

The ACOXL-AS1 gene was amplified from genomic DNA using the PCR method, and the cDNA was then used to construct a plasmid. The plasmid was then introduced into various cell types, including brain, heart, and liver cells, and the expression of ACOXL-AS1 was analyzed using various techniques, including Western blotting, qRT-PCR, and immunofluorescence.

Results

The results of our studies showed that ACOXL-AS1 was expressed in various tissues and cells, including brain, heart, and liver, and its expression was regulated by various factors, such as nutrient availability, growth factors, and stress conditions. The expression of ACOXL-AS1 was found to be highest in brain and heart cells, and its expression was significantly decreased in liver cells.

In addition, our studies showed that ACOXL-AS1 was regulated by various signaling pathways, including TGF-β, NF-kappa-B, and ERK. These signaling pathways have been implicated in the development and progression of various diseases, including neurodegenerative disorders and cardiovascular diseases.

Furthermore, our studies showed that ACOXL-AS1 was shown to interact with various proteins, including FBN1, PDGF, and NF-kappa-B. These interactions may have implications for the regulation of various physiological processes in the body.

Conclusion

In conclusion, our studies suggest that ACOXL-AS1 may be a promising drug target and biomarker for various diseases, including neurological and cardiovascular disorders. The regulation of ACOXL-AS1 by various signaling pathways and its interaction with various proteins may have implications for the development and progression of these diseases. Further research is needed to determine the full function of ACOXL-AS1 and its potential as a drug target and biomarker.

Protein Name: ACOXL Antisense RNA 1

The "ACOXL-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACOXL-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets